Business Wire

Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer

Jaa

Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005126/en/

Biliary tract cancer is a rare tumour with approximately 8,000 patients diagnosed in the US every year and 10,571 in Europe.4,5 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of care is generally palliative.1,2 The five-year survival rates for patients with biliary tract cancer are very low, approximately 15%.6

Dr Thomas Mehrling, CEO of Mundipharma EDO added: “We are pleased that the FDA has recognised etoposide toniribate as a potential treatment for relapsed/refractory biliary tract cancer. As a company we are focused on developing treatments for rare and difficult-to-treat cancers and getting them to patients as rapidly as possible. We look forward to accelerating the development of etoposide toniribate, in conjunction with Imbrium Therapeutics, with a global Phase III trial with sites in EU, US, Australia and other countries.”

We are pleased that the FDA has granted Orphan Drug Designation for etoposide toniribate in recognition of its potential as an important clinical advance for patients suffering from relapsed/refractory biliary tract cancer, a patient population that has limited treatment options,” said Paul Medeiros, President of Imbrium Therapeutics. “This designation represents Imbrium’s first milestone in oncology and underscores our commitment to advance the clinical development of oncology chemotherapeutics while actively collaborating to advance treatments across our therapeutic portfolio.”

Etoposide toniribate has shown encouraging data in Phase II trials and this data has been key in securing the ODD.7 This news is in addition to the European Medicines Agency (EMA) also granting orphan designation on 4 June 2014.8 As with the FDA, this designation allows protocol assistance, reduced fees and 10-years marketing exclusivity in that disease after approval. It can also lead to speedier reimbursement in many EU member states.

To find out more about this treatment or the Mundipharma EDO oncology clinical trials programme visit: www.edoncology.com/clinical-trials

-Ends-

Notes to editors:

For further information please visit https://www.edoncology.com/latest-news/

References:

1. Valle JW, et al. Ann Oncol. 2016;27(S5):v27–v37.
2. NCI. https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq. Accessed 14.02.19
3. US FDA. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=671318 Accessed 14.02.19
4. ACS. https://www.cancer.org/cancer/bile-duct-cancer/about/key-statistics.html. Accessed 14.02.19
5. ECIS. https://ecis.jrc.ec.europa.eu/. Accessed 14.02.19
6. CCF. https://cholangiocarcinoma.org/. Accessed 14.02.19
7. Pape UF, et al. J Clin Oncol. 2019;3(S4):264.
8. EMA. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3141270 Accessed 14.02.19

Date of Preparation: February 2019

Contact information

Ex USA
Tiffany Fretwell
tiffany.fretwell@mundipharma.com
+44 (0) 1223 393 361

Helen Laurence
helen@makarahealth.com
Tel: +44 (0) 23 81 247 327

USA
media@imbriumthera.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

BrandSafway Selects Rimini Street Application Management Services for Salesforce26.6.2019 16:00:00 EESTTiedote

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that BrandSafway, a global leader in access, industrial services and forming and shoring solutions for the industrial, commercial and infrastructure markets, has selected Rimini Street Application Management Services (AMS) for Salesforce for its Salesforce Sales Cloud system. BrandSafway has been leveraging Rimini Street support for its Oracle Database, E-Business Suite and JD Edwards software products since 2014, and now, BrandSafway is expanding its support service scope with Rimini Street to maximize the value and business impact of Salesforce and the Salesforce Sales Cloud system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190626005022/en/ BrandSafway Selects Rimini Street Application Management Servi

Jabil Packaging Solutions Launches New Sustainable Packaging Services; Accelerates Sustainable Packaging Innovation26.6.2019 15:45:00 EESTTiedote

Jabil Packaging Solutions (JPS), a division of Jabil Inc. (NYSE: JBL), today introduced a new suite of Sustainable Packaging Services , that enable packaged goods brands to design and deliver innovative new sustainable packaging formats into the marketplace at speed. Today, companies producing Consumer Packaged Goods (CPG) are at a turning point. They must find smart ways to make their products and packaging sustainable or face increasing regulations, taxes and pushback from consumers. Companies are trying to respond to sustainability mandates and want to do the right thing for the environment. Yet assessing what is needed, sourcing the right materials and designing products that meet their corporate sustainability goals is extremely complex due to the interdependencies and expertise required for end-to-end sustainable development. “For CPGs, there has never been a bigger challenge than the transition to a truly sustainable business model,” said Jason Paladino, JPS Vice President of Te

Moody’s Analytics Wins Enterprise-Wide Stress Testing Product of the Year at Risk Technology Awards26.6.2019 13:00:00 EESTTiedote

Moody’s Analytics, a global provider of financial intelligence, has won Enterprise-Wide Stress Testing Product of the Year at the 2019 Risk Technology Awards. It’s one of six categories won across finance, accounting, regulatory, and credit functions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190626005246/en/ Traditionally, stress testing exercises have required the participation of many groups within an institution and often took several months to complete. Today, banks must be able to respond to regulatory and management requests faster, while also extracting business value from the results. Moody’s Analytics helps banks overcome the challenges of stress testing. Our solutions improve data quality and integrity and make efficient use of resource and technology investments, while delivering industry-leading Moody’s Analytics modeling expertise. “Stress testing plays a critical role in how banks manage risk. Understandi

Tech Giant Alibaba Cloud Partners With UAE’s Group 42 to Host First MEA Internet Summit26.6.2019 12:19:00 EESTTiedote

Alibaba Cloud, the data intelligence backbone of Alibaba Group, today held its inaugural Middle East and Africa (MEA) Internet Summit in partnership with UAE-based Artificial Intelligence (AI) and Cloud Computing leader Group 42. Drawing the participation of tech experts and executives from the region’s top 100 internet companies, the summit took place during the Ghyma Conference 2019. Among the distinguished guests were HE Saif Mohammed Al Hajri, Chairman of the Department of Economic Development Abu Dhabi, His Excellency Mohammed Gheyath, Executive Director Information Security Operations, Abu Dhabi Digital Authority, Ibrahim Ajami, Head of Mubadala Ventures, Peng Xiao, CEO of Group 42, and Selina Yuan, President of Alibaba Cloud Intelligence International. Panelists and speakers covered an extensive range of topics over 10 keynote speeches. These included maximising the potential of cloud and AI, leveraging the internet to thrive in the new digital age, taking e-commerce to the next

SIGMOLECS®: the Most Advanced Technology Available for Regenerative Medicine26.6.2019 12:00:00 EESTTiedote

Contrad Swiss, a pharmaceutical company focused on breakthrough, innovative products that reframe the world of medicine, announces a new partnership with Dr JO Serrentino to bring to the market effective biomedical remedies unlike any other. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190626005031/en/ Photo by Contrad Swiss SIGMOLECS® Technology was conceived and engineered by Dr Serrentino exclusively for Contrad Swiss. SIGMOLECS® uses the highest bioavailable signaling molecules to summon and target biological pathways for precise programming at the cellular level. The result is like a program code of the cells, deploying them to organize into specific patterns. SIGMOLECS® talks to the cells in their language. ACTV8SKN® – Actuator - contains the exclusive SIGMOLECS® Technology. ACTV8SKN® is an odorless fluid gel of peptide-bonded amino acids, specifically engineered for a complete signaling spectrum that awakens cell cy

Secure-24, an NTT Communications Company, to Acquire Symmetry, Leading SAP Managed Service Provider in the U.S.26.6.2019 09:00:00 EESTTiedote

NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO:9432), and Symmetry Holding Inc. (Symmetry), a U.S.-based leading provider of SAP managed services, announced today that Secure-24 Intermediate Holdings, Inc. (Secure-24), wholly owned subsidiary of NTT Com, entered into a definitive agreement on June 26 (Japan Standard Time), pursuant to which Secure-24 will wholly acquire Symmetry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190625006084/en/ Managed services are one of the key capabilities NTT Com is strengthening to support its clients’ digital transformations as a DX Enabler™. Secure-24 has been playing key roles for delivering such capabilities especially in the U.S. market. Symmetry possesses extensive expertise in SAP managed services, which it delivers to large enterprise clients in diverse industries including consumer products, life s

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme